BMRN - RICHARD MEIER At Biomarin Pharmaceutical Capitalizes: Options Exercised Resulting In $104K | Benzinga
Disclosed in a recent SEC filing on June 4, MEIER, Board Member at Biomarin Pharmaceutical (NASDAQ:BMRN), made a noteworthy transaction involving the exercise of company stock options.
What Happened: In an insider options sale disclosed in a Form 4 filing on Tuesday with the U.S. Securities and Exchange Commission, MEIER, Board Member at Biomarin Pharmaceutical, exercised stock options for 6,600 shares of BMRN. The transaction value amounted to $104,412.
Biomarin Pharmaceutical shares are currently trading down by 0.21%, with a current price of $78.92 as of Wednesday morning. This brings the total value of MEIER's 6,600 shares to $104,412.
Delving into Biomarin Pharmaceutical's Background
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
Financial Milestones: Biomarin Pharmaceutical's Journey
Revenue Growth: Biomarin Pharmaceutical displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 8.79%. This indicates a ...